"Pathophysiologic mapping" of venous thromboembolism: Opportunities for radiolabeled peptides

Quarterly Journal of Nuclear Medicine

Volumn 47, Issue 4, 2003, Pages 292-320

  Bernarducci, Marc P ^a,b  

^a Society of Nuclear Medicine   (United States)

^b NONE   (United States)

Author keywords

Radionuclide imaging; Radiopharmaceuticals; Thromboembolism; Venous thrombosis

Indexed keywords

RADIOPHARMACEUTICAL AGENT; TECHNETIUM 99M;

ARTICLE; CLINICAL PRACTICE; CLINICAL RESEARCH; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC TEST; GENERAL PRACTITIONER; HUMAN; ISOTOPE LABELING; NUCLEAR MEDICINE; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; SCINTISCANNING; UNITED STATES; VENOUS THROMBOEMBOLISM;

HUMANS; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES; PEPTIDES, CYCLIC; RADIOPHARMACEUTICALS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 1842474334     PISSN: 11243937     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (68)

1. Gray HW. The natural history of venous thromboembolism: Impact on ventilation/perfusion scan reporting. Semin Nucl Med 2002;32: 159-72.
2. American Public Health Association and Centers for Disease Control Gather to Elevate Awareness of Deep-Vein Thrombosis as Major Health Threat Recognizing Risk Factors and Implementing Preventive Measures Can Save Lives [press release]. Washington, DC: Public Health Leadership Conference on Deep-Vein Thrombosis; February 26, 2003.
3. Hirsch J, Hoak J. Management of deep vein thrombosis and pulmonary embolism. Circulation 1996;93:2212-45.
4. Dalen JE, Alpert JS. Natural history of pulmonay embolism. Prog Cardiovasc Dis 1975;17:259-70.
5. Hull RD, Hirsch J, Carter CJ, Jay RM, Dodd PE, Ockelford PA et al. Pulmonary angiography, ventilation lung scanning, and venography for clinically suspected pulmonary embolism with abnormal perfusion lung scan. Ann Intern Med 1983;98:891-9.
6. Nicolaides AN, Kakkar VV, Field ES, Renney JT. The origin of deep vein thrombosis: a venographic study. Br J Radiol 1971;44:653-63.
7. Alpert JS, Dalen JE. Epdiemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 1994;36:417-22.
8. Kakkar VV, Howe CT, Flanc C, Clarke MB. Natural history of post-operative deep-vein thrombosis. Lancet 1969;2:230-2.
9. Cogo A, Lensing AW, Prandoni P, Hirsch J. Distribution of thrombosis in patients with symptomatic deep-vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med 1993;153:2777-80.
10. Sevitt S. The structure and growth of valve pocket thrombi in femoral veins. J Clin Pathol 1974;27:517-28.
11. Kleiman NS, Raizner AE, Jordan R, Wang AL, Norton D, Mace KF et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: implications for inhibition of the internal pool of GPIIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-71.
12. Quinn MJ, Murphy RT, Dooley M, Foley JB, Fitzgerald DJ. Occupany of the internal and external pools of glycoprotein IIb/IIIa following abciximab bolus and infusion. J Pharmacol Exp Ther 2001;297:496-500.
13. Gawaz M, Ruf A, Pogatsa-Murray G, Dickfeld T, Rudiger S, Tanbitz W et al. Incomplete inhibition of platelet aggregation and glycoprotein IIb-IIIa receptor blockade by abciximab: Importance of internal pool of glycoprotein IIb-IIIa receptors. Thromb Haemost 2000;83:915-22.
14. Anand SS, Wells PS, Hunt D, Brill-Edwards P, Cook D, Ginsberg JS et al. Does this patient have deep vein thrombosis? JAMA 1998;279:1094-9.
15. Taillefer R. Radiolabeled peptides in the detection of deep venous thrombosis. Semin Nucl Med 2001;31:102-23.
16. 99mTc-labelled peptide-based radiopharmaceuticals. An overview. Nucl Med Commun 1999;20: 1093-112.
17. Dean RT, James JL, Lees RS et al. Peptides in biochemical sciences: Principles and practice. In: Martin-Comin J, Thakur ML, Piera C et al, editors. Radiolabeled blood elements. New York, NY: Plenum Press; 1994.p.195-9.
18. Weiner RE, Thakur ML. Radiolabeled peptides in diagnosis and therapy. Semin Nucl Med 2001;31:296-311.
19. Thakur ML. Scintigraphic imaging of venous thrombosis: the state of the art. Thromb Haemorrh Disorders 1992;5:29-36.
20. Loscalzo J, Rocco TP. Imaging arterial thrombi: an elusive goal. Circulation. 1992;85:382-5.
21. Som P, Oster ZH. Thrombus-specific imaging: approaching the elusive goal. J Nucl Med 1994;35:202-3.
22. Knight LC. Radiolabeled peptide ligands for imaging thrombi and emboli. Nucl Med Biol 2001;28:515-26.
23. Ruggeri ZM. Platelets in otherothrombosis. Nature Med 2002;8:1227-34.
24. Charo IF, Kieffer N, Phillips DR. Platelet membrane glycoproteins. In: Colman RW, Hirsch J, Marder VJ, editors. Hemostasis and thrombosis: basic principles and clinical practice. Philadelphia, PA: JB Lippincott Co; 1994.p.489-507.
25. AcuTect [prescribing information]. CIS-US, Inc (Bedford, MA), Inc; June 2001.
26. Data on file. Berlex Laboratories Bedford, MA: CIS-US; 2003.
27. 99mTc-P280) in detection of acute venous thrombosis: Correlation with contrast venogram. J Nucl Med 2001;40:2029-35.
28. 99mTc-P280 detection of deep venous thrombosis (DVT) in patients with a prior history of DVT. J Nucl Med 1997;38:98F.
29. 99mTc P280 to contrast venography (CV) for detection and localization of acute deep venous thrombosis (DVT). J Nucl Med. 1997;38:98.
30. 99mTc P280 for the detection and localization of acute deep venous thrombosis. J Nucl Med 1997;38:98.
31. 99mTc-labeled synthetic peptide P280. J Nucl Med 1995;36:1384-91.
32. 99mTc-apcitide scintigraphy with contrast venography for imaging acute deep venous thrombosis. J Nucl Med 2000;41:1214-23.
33. 99mTc-labeled platelet glycoprotein GP IIb/IIIa receptor antagonist in patients with acute deep vein thrombosis and a history of deep vein thrombosis. Arch Intern Med 2003;163:452-6.
34. Scharn DM, Oyen WJ, Klemm PL, Wijnen MH, vanderVliet JA. Assessment of prosthetic vascular graft thrombogenicity using the technetium-99m labeled glycoprotein IIb/IIIa receptor antagonist DMP444 in a dog model. Cardiovasc Surg 2002;10:566-9.
35. Klem JA, Schaffer JV, Crane PD, Barrett JA, Henry GA, Canestri L et al. Detection of deep venous thrombosis by DMP 444, a platelet IIb/IIIa antagonist. A preliminary report. J Nucl Cardiol 2000;7:359-64.
36. 99mTc-DMP 444 scintigraphy for detection of acute deep venous thrombosis (DVT)? J Nucl Med [abstract] 1999;40:152P.
37. 99mTc DMP 444 peptide scintigraphy for detection of acute deep vein thrombosis: A mutlicenter clinical trial [abstract]. J Nucl Med 2000;41:12P.
38. Borg BD, Tulchinsky M, Pellegrini VD. Detection of deep venous thrombosis by thromboscintigraphy with DMP-444 after total knee arthroplasty [abstract]. J Nucl Med 2000;41:12P.
39. 99mTc-bitistatin, a platelet-binding polypeptide from viper venom. J Nucl Med 2000;41:1056-64.
40. 3 receptor on resting and activated human platelets. Biochem J 1994;301:429-36.
41. Knight LC, Maurer AH, Romano JE. Comparison of iodine-123-disintegrins for imagin thrombi and emboli in a canine model. J Nucl Med 1996;37:476-82.
42. 99mTc-labeled bitistatin, an agent for imaging of pulmonary emboli. J Labeled Comp Radiopharm 1997;40:461-2.
43. Knight LC, Baidoo KE, Romano JE et al. Production recombinant bitistatin and comparison with native bitistatin for imagin thrombi and emboli [abstract]. Nucl Med Commun 2000;21:573.
44. 99mTc-FBD (fibrin binding domain of fibronectin) scintigraphy in patients with acute deep vein thrombosis (ADVT): results of the Phase II Multicenter Trial [abstract]. Society of Nuclear Medicine Annual Meeting, June 2000, St. Louis.
45. Anderson FA jr, Wheeler HB, Goldberg RT, et al. A population-based perspective of the hospital incidence and case facility rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Ann Intern Med 1991;151:933-8.
46. Line BR. Pathophysiology and diagnosis of deep venous thrombosis. Semin Nucl Med 2001;31:90-101.
47. Senior RM. Pulmonary embolism. In: Wyngaarden JB, Smith LH, Bennett JC, editors. Cecil's Textbook of Medicine. Vol. 1. 19th
48. Weitz J, Hirsh J. New anticoagulant drugs. Chest 2001;119:95S-107S.
49. Ansell J, Hirsh J, Dalen J Bussey H, Anderson D, Poller L et al. Managing oral anticoagulant therapy. Chest 2001;119(1 Suppl.):22S-38S.
50. Ridker PM. Long-term, low-dose warfarin among venous thrombosis patients with and without factor V Leiden mutation: rationale and design for the prevention of recurrent venous thromboembolism (PREVENT) trial. Vasc Med 1998;3:67-73.
51. Schulman S, Rhedin A, Lindmarker P, Carlsson A, Larfars G, Nicol P et al. A comparison of six weeks with six months of oral anticoagulant therapy after first episode of venous thromboembolism. Duration of Anticoagulation Trial Study Group. N Engl J Med 1995;332:1661-5.
52. Schulman S, Granqvist S, Holmström M, Carlsson A, Lindmarker P, Nicol P et al. The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med 1997;336:393-8.
53. Ridker PM, Goldhaber SZ, Danielson E, Rosenberg Y, Eby CS, Deitcher SR et al. for the PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-34.
54. Nicolaides AN, Kakkar VV, Field ES, Renney JT. The origin of deep vein thrombosis: a venographic study. Br J Radiol 1971;44:653-63.
55. Alpert JS, Dalen JE. Epdiemiology and natural history of venous thromboembolism. Prog Cardiovasc Dis 1994;36:417-22.
56. Cogo A, Lensing AW, Prandoni P, Hirsch J. Distribution of thrombosis in patients with symptomatic deep-vein thrombosis. Implications for simplifying the diagnostic process with compression ultrasound. Arch Intern Med 1993;153:2777-80.
57. Philbrick JT, Becker DM. Calf deep vein thrombosis. A wolf in sheep's clothing? Arch Intern Med 1988;148:2131-8.
58. Lagerstedt CI, Olsson CG, Fagher BO, Oqvist BW, Albrechtsson U. Need for long-term anticoagulant treatment in symptomatic calfvein thrombosis. Lancet 1985;2:515-8.
59. Pinede L, Ninet J, Duhaut P, Chabaud S, Demolonbe-Rague S, Duren I et al. Comparison of 3 and 6 months of oral anticoagulant therapy after a first episode of proximal deep vein thrombosis or pulmonary embolism and comparison of 6 and 12 weeks of therapy after isolated calf deep vein thrombosis. Circulation 2001; 103:2453-60.
60. Strandness DE, Langlois Y, Cramer M et al. Long-term sequelae of acute venous thrombosis. JAMA 1983;250:1289-92.
61. Prandoni P, Lensing AWA, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996;125:1-7.
62. Salzman EW, Hirsh J. The epidemiology, pathogenesis, and natural history of venous thrombosis. In: Coleman RW, Hirsh J, Marder VJ et al. editors. Hemostasis and thrombosis: basic principles and clinical practice. 3rd ed. Philadelphia, PA: Lippincott; 1993.p.1275-96.
63. Passman MA, Moneta GL, Taylor LM et al. Pulmonary embolism is associated with the combination of isolated calf vein thrombosis and respiratory symptoms. J Vasc Surg 1998;28:67-73.
64. Kazmers A, Groehn H, Meeker C. Acute calf vein thrombosis: outcomes and implications. Am Surg 1999;65:1124-8.
65. Ohgi S, Tachibana M, Ikebuchi M, Kanaoka Y, Maeda T, Mori T. Pulmonary embolism in patients with isolated soleal vein thrombosis. J Vasc Dis 1998;9:759-64.
66. 99mTc apcitide scintigraphy. Neuroradiology 2002;44:819-21.
67. Fihn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996;124:970-9.
68. Kakkar VV. New Insight in the diagnosis of venous thromboembolism. Preliminary phase 3 clinical trial data presented at: 44th Annual Meeting of the American Society of Hematology. December 6, 2002; Philadelphia, PA.